Lord, Abbett & Co. LLC Genmab A/S Transaction History

Lord, Abbett & Co. LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Oct 07, 2024	BUY	$33.8 - $47.06 $21.8 Million - $30.4 Million	645,551 New	645,551 $27.4 Million
Q4 2022 Feb 10, 2023	BUY	$33.8 - $47.06 $16.1 Million - $22.4 Million	475,579 Added 279.8%	645,551 $27.4 Million
Q3 2022 Nov 14, 2022	SELL	$31.52 - $373.61 $1.61 Million - $19.1 Million	-51,113 Reduced 23.12%	169,972 $5.46 Million
Q2 2022 Aug 12, 2022	BUY	$26.83 - $38.57 $588,408 - $845,878	21,931 Added 11.01%	221,085 $7.18 Million
Q1 2022 May 13, 2022	SELL	$30.95 - $39.68 $306,652 - $393,149	-9,908 Reduced 4.74%	199,154 $7.21 Million
Q4 2021 Feb 11, 2022	SELL	$35.87 - $47.12 $190,111 - $249,736	-5,300 Reduced 2.47%	209,062 $8.27 Million
Q3 2021 Nov 09, 2021	SELL	$41.55 - $48.72 $555,731 - $651,630	-13,375 Reduced 5.87%	214,362 $9.37 Million
Q2 2021 Aug 11, 2021	BUY	$32.88 - $44.57 $3.51 Million - $4.75 Million	106,606 Added 88.01%	227,737 $9.3 Million
Q1 2021 May 11, 2021	BUY	$30.92 - $44.4 $3.75 Million - $5.38 Million	121,131 New	121,131 $3.98 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.